** Shares of cell-based therapy company THMO.O fall 7% to
a two-week low of $2.14
** H.C. Wainwright cuts PT to $8.50 from $9.50 after THMO on
Thursday reported a 42% plunge in Q3 rev as demand for its cord
blood banking products was hurt by the COVID-19 pandemic
urn:newsml:reuters.com:*:nPn2gwDrZa
** Brokerage says despite recent positive news on vaccine
development, it may be 12-18 months before an effective vaccine
becomes widely available; lowers Q4 rev estimate to $2.6 mln
from $6.1 mln
** Expects the cord blood banking industry to recover over
2021 and 2022 as the pandemic subsides
** With the growing prominence of cell therapies, there
would be growing demand for THMO's cell processing products as
well - brokerage
** Believes cell processing products and services remain the
most important long-term growth drivers for co
** Up to Thursday's close, stock down 47.7% this year
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))